Dr. R. Rox Anderson to Join LumaMed Board of Directors

ATLANTA, GA and BOSTON, MA--(Marketwire - Oct 13, 2011) - LumaMed announced today that Dr. R. Rox Anderson has agreed to join the Company's Board of Directors. Dr. Anderson practices dermatology at Massachusetts General Hospital and is the Director of the Wellman Center for Photomedicine at Massachusetts General Hospital. In addition, Dr. Anderson is a Professor of Dermatology at Harvard Medical School and is an affiliated faculty member at the Massachusetts Institute of Technology (MIT).

"The addition of Dr. Anderson to our Board of Directors is an important milestone for our company," said Mark A. Samuels, chief executive officer of LumaMed. "His enthusiasm and expertise will be invaluable as we develop products that can improve surgical efficiency and outcomes for breast, skin and other cancers. In the case of Mohs surgery for skin cancer, our approach is expected to reduce the number of average excisions it currently takes to remove the cancer. In the case of breast cancer, LumaMed believes it has the potential to reduce or eliminate a high percentage of the 30-to-40% of lumpectomies that require a second costly surgery because positive margins are identified in subsequent histopathology."

New data obtained by Dr. Anna Yaroslavsky's laboratory at the University of Massachusetts Lowell has shown excellent results in breast cancer identification using techniques licensed by LumaMed. LumaMed plans to focus on the skin and breast cancer market for its initial products. LumaMed intends to commence product development upon completion of its initial funding round.

Dr. Anderson has made many contributions to the understanding and development of laser-tissue interactions, tissue optics, photodynamic therapy, and optical diagnostics. He is the former Chairman of the Research and Development Committee, American Society for Lasers in Medicine and Surgery; Clinical Fellow and Director Dermatology Laser Center, Massachusetts General Hospital; and Director Wellman Laboratories of Photomedicine. He is a graduate of Harvard Medical School and is a practicing clinician in dermatology. He has authored over 156 peer review articles and has been a contributing author on over 21 textbooks on the use of lasers in medicine and surgery. He serves on several editorial boards of the industry's most respected journals and has won over 12 awards and honors for his contribution to the field of lasers in medicine and surgery. Dr. Anderson has over 41 patents to his credit.

LumaMed finalized its licensing agreement with Massachusetts General Hospital on June 20, 2011. The license includes six issued U.S. patents and several U.S. and international applications relating to the portfolio which describes techniques for polarization and fluorescence imaging. Dr. Yaroslavsky and Dr. Anderson are inventors of the technology.

LumaMed's cancer imaging technology addresses an estimated multibillion dollar worldwide market opportunity for products that improve efficiency and efficacy in cancer removal procedures. Cancer margin delineation is critical in instances where tissue preservation is important, such as breast, skin, head and neck, prostate and brain surgeries.

About LumaMed, LLC.
LumaMed is developing devices that provide rapid, easy and improved imaging of cancer based on patented polarization and fluorescence imaging technology. LumaMed's revolutionary cancer visualization tools enable real-time imaging of cancer margins during surgery with an accuracy that rivals that of conventional pathology. In addition to the initial focus on breast and skin cancer, the company believes the approach can be used with other cancers such as prostate and head & neck cancers. LumaMed has licensed polarization imaging technology from both Massachusetts General Hospital and Providence Hospital in Oregon. LumaMed products are not intended to replace pathology, have not been cleared by the FDA for sales in the U.S. and are not presently being offered for sale. For more information, visit www.lumamed.com.